Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q1 EPS of ($0.34), $0.01 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $12.13 million versus the consensus estimate of $12.97 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.